Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Biologic Clear all
Terminated Phase 2 Interventional

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00015912
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Interventions
recombinant interferon alfa, thalidomide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Behavior, Biology and Well-Being Study

NCT05183867
View directory record Official record
Conditions
Depression, Psychological Distress
Interventions
Healthy Minds Program
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Leptin Biology in Adipose Tissue

NCT01800864
View directory record Official record
Conditions
Obesity
Interventions
obesity
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 3 Interventional

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

NCT00051467
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TNFerade
Genetic
Lead sponsor
GenVec
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional

Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

NCT00003585
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, recombinant interferon alfa, fluorouracil, isotretinoin, surgical procedure
Biological · Drug · Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depression, Aging, Stress and Heart Health Study

NCT05570721
View directory record Official record
Conditions
Menopause, Depression, Heart Disease in Women, Stress
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Enrolling by invitation No phase listed Observational

Comparison of Human Allograft to Apligraf for Venous Leg Ulcers

NCT02047084
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Not listed
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
21 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

NCT00397384
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 10, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

NCT05150691
View directory record Official record
Conditions
HER2-positive Advanced Solid Tumor
Interventions
DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
Biological · Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Cerritos, California • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional

The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer

NCT05943210
View directory record Official record
Conditions
Rectal Cancer
Interventions
Short Course Radiation Therapy (scRT), Total Mesenteric Excision (TME)
Radiation · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Chicago, Illinois • New Brunswick, New Jersey • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Microbiome of Urologic Chronic Pelvic Pain Syndrome

NCT03027076
View directory record Official record
Conditions
Prostatitis, Chronic Prostatitis, Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome
Interventions
Genitourinary Specimen Collection, Collect midstream urine samples
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 10, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

NCT01636817
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
92
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

NCT01387555
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Withdrawn Phase 2 Interventional

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

NCT00308204
View directory record Official record
Conditions
Discoid Lupus Erthematosus of the Scalp
Interventions
Raptiva
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 10, 2026, 5:33 PM EDT
Terminated Not applicable Interventional

Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions

NCT01452516
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Interventions
nanOss Bioactive Bone void filler, Interbody FCage
Device
Lead sponsor
Pioneer Surgical Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 10, 2026, 5:33 PM EDT
Completed No phase listed Observational

Systems Biology Approach to Cognitive Impairment After SepsiS

NCT03015584
View directory record Official record
Conditions
Sepsis, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 10, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional Results available

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

NCT05446129
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ezabenlimab, BI 765063, Pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Beta Glucan 500 and Biological Age and Immune Age

NCT07104929
View directory record Official record
Conditions
Aging
Interventions
Beta Glucan
Dietary Supplement
Lead sponsor
OvationLab
Network
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

A Study of DF6002 Alone and in Combination With Nivolumab

NCT04423029
View directory record Official record
Conditions
Solid Tumors
Interventions
DF6002, Nivolumab
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
21
States / cities
Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

NCT06027437
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danicamtiv
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 10, 2026, 5:33 PM EDT
Completed No phase listed Observational

Fungicide Exposure Assessment Among Apple and Peach Farmers in the Argicultural Health Study

NCT00342394
View directory record Official record
Conditions
Pesticides, Occupational Exposure
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 10, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Meso BioMatrix Device for Breast Reconstruction

NCT01823107
View directory record Official record
Conditions
Breast Cancer
Interventions
Meso BioMatrix Device
Device
Lead sponsor
Kensey Nash Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Detroit, Michigan • Garden City, New York • Bala-Cynwyd, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 10, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers

NCT05698212
View directory record Official record
Conditions
Endometriosis, Diagnosis
Interventions
MetriDx
Diagnostic Test
Lead sponsor
Hera Biotech, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Saginaw, Michigan • Corpus Christi, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 10, 2026, 5:33 PM EDT